ANDA 78922, held by PharmoBedient. Zidovudine.
As of Nov 21, 2026, ANDA 78922 (Zidovudine), held by PharmoBedient, was first approved by FDA on Feb 14, 2008, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 14, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine300MG · tablet;oral | Zidovudine | Discontinued |
| Feb 12, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 26, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 26, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 30, 2012 | Supplement 5Labeling | Approved | None posted |
| Mar 2, 2011 | Supplement 4Labeling | Approved | None posted |
| Feb 14, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters